Pharmasyntez is cooperating with scientists from the Institute for Translational Medicine and Biotechnology of Sechenov University to create innovative cancer drugs.
Original targeted drugs will be used in the treatment of tumors of the thyroid gland and central nervous system, breast cancer, Wilms tumor, esophageal cancer, melanoma, and other oncological diseases. The resulting technological platform may later ensure a breakthrough for similar drug discovery projects aimed at developing therapies for cancer and other serious diseases.
The incidence of malignant neoplasms is currently increasing all over the world. More than half a million cases of malignant neoplasms were first diagnosed in the Russian Federation in 2021. In 40% of cases, the disease is detected in stages 3 and 4.
“Scientists at Sechenov University are developing a platform to search for new molecules that block the development of pathologies in cancer. They will become the basis for the creation of highly effective drugs for the treatment of cancer both in patients with the initial stages and severe forms of the disease, to maintain the quality of life of patients. Over the centuries of the fight against tumors, treatment strategies have evolved from surgery, radiation therapy and chemotherapy to targeted therapy, which is effective due to its targeted action. This is what our research group is doing,” said Vladimir Trukhan, the project manager, Deputy Director for Strategic Development of the Institute for Translational Medicine and Biotechnology of Sechenov University, Candidate of Chemical Sciences.
According to him, one of the main problems in cancer treatment is the development of the body’s resistance to therapy, which leads to the development of new malignant neoplasms. To solve this problem, it is necessary to develop multi-targeted drugs that act on various types of tumors.
Roman Ivanov, Director of Innovation Development at AO Pharmasyntez, believes:
“Sechenov University is a recognized leader among Russia’s medical schools. Due to the competencies of its employees, as well as its facilities and resources, we can expect to succeed in this challenging task — the search for new antitumor drugs, as, according to statistics, their development is the most risky and costly.”